| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Support Directorate, SAIC-Frederick Inc., NCI-Frederick, Frederick, Maryland, 21702;
2 Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892;
3 Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, 20892
The Food and Drug Administration (FDA) recently introduced the Exploratory Investigational New Drug Guidance to expedite the clinical evaluation of new therapeutic and imaging agents. Early clinical studies performed under the auspices of this guidance, so-called "Phase 0" trials, have been initiated at the National Cancer Institute to integrate qualified pharmacodynamic biomarker assays into first-in-human cancer clinical trials of molecularly targeted agents. The goal of this integration is to perform molecular proof-of-concept investigations at the earliest stage of cancer drug development. Phase 0 trials do not offer any possibility of patient benefit; instead, intensive, real-time pharmacodynamic and pharmacokinetic analyses of patient tumor samples and/or surrogate tissues are performed to inform subsequent trials. Phase 0 studies do not replace formal Phase I drug safety testing and require a substantial investment of resources in assay development early on; however, they offer the promise of more rational selection of agents for further, large-scale development as well as the molecular identification of potential therapeutic failures early in the development process.
This article has been cited by other articles:
|
|
 |
|
  A. Idbaih, F. Ducray, M. Sierra Del Rio, K. Hoang-Xuan, and J.-Y. Delattre Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors Oncologist, September 1, 2008; 13(9): 978 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Murgo, S. Kummar, L. Rubinstein, M. Gutierrez, J. Collins, R. Kinders, R. E. Parchment, J. Ji, S. M. Steinberg, S. X. Yang, et al. Designing Phase 0 Cancer Clinical Trials Clin. Cancer Res., June 15, 2008; 14(12): 3675 - 3682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Abdoler, H. Taylor, and D. Wendler The Ethics of Phase 0 Oncology Trials Clin. Cancer Res., June 15, 2008; 14(12): 3692 - 3697. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |
